Velzatinib not checked

GSK · IDRX-42 · GSK6042981/IDRX-42

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
8 active
8 in total · 3 in the EU
Targets
LCK · CSF-1R · FLT3 · KIT · PDGFRB · PDGFRA
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
How it’s given
“Administered at assigned doses and schedules once or twice daily in continuous cycles of 28 days each.”In the company’s words, NCT05489237 on ClinicalTrials.gov
Tested for
Gastrointestinal Neoplasms (7 trials), Gastrointestinal Stromal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
Main trialPhase 3
“The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib. Participants whose disease worsens after receiving sunitinib in this study may cross over to receive GSK6042981, at investigator's discretion and if additional eligibility criteria…”In the company’s words, NCT07218926 on ClinicalTrials.gov
Other names
IDRX-42 · GSK6042981/IDRX-42 · GSK6042981

Other drugs for Gastrointestinal Neoplasms

All 553 drugs for Gastrointestinal Neoplasms

Coming up8

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 May 2028 A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Phase 3Recruiting 30 Aug 2032 A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
Phase 2Recruiting 29 Nov 2027 A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib
Phase 2Not yet recruiting 31 Jan 2031 A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)
Phase 1Not yet recruiting 12 Jan 2027 A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy Participants
Phase 1Active, not recruiting 10 Mar 2027 First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
Phase 1Not yet recruiting 9 Sep 2027 A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on Velzatinib
Phase 1Not yet recruiting 25 Apr 2028 A Study to Investigate the Effects of Impaired Hepatic Function on Velzatinib
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Velzatinib

Following is part of Solo: you see every change to Velzatinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in